A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2011
03/10/2011	US20110059046 Derivatives of gefitinib
03/10/2011	US20110059045 Pharmaceutical composition for cancer treatment
03/10/2011	US20110059043 Chemical compounds
03/10/2011	US20110059040 Compositions and methods for inhibiting viral and bacterial activity
03/10/2011	US20110059039 Use of peo-pbo block copolymers in ophthalmic compositions
03/10/2011	US20110059038 Method of stabilizing a polysiloxane emulsion and compositions containing stabilized emulsions
03/10/2011	US20110059037 Polymeric compositions containing ir-emitting/absorbing additives and shaped articles comprised thereof
03/10/2011	US20110059036 Nitric oxide-releasing polymers
03/10/2011	US20110059032 Hydrocarbon Mixtures and use Thereof
03/10/2011	US20110059031 Oral Cereal Beta Glucan Compositions
03/10/2011	US20110059026 Pharmaceutical dosage form bearing pregnancy-friendly indicia
03/10/2011	US20110059019 Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
03/10/2011	US20110056863 Adhesive preparation containing donepezil, and package of the same
03/10/2011	DE19605659B4 Verwendung einer Kombination von beta Caroten und Vitamin E-Derivaten zur Behandlung epithelialer Differenzierungsstörungen Using a combination of beta carotene and vitamin E derivatives for the treatment of epithelial differentiation disorders
03/10/2011	DE10354893B4 Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen Use of deoxypeganine for the treatment of schizophrenic psychoses
03/10/2011	DE102009040870A1 Composition, useful for treating and prophylaxis of affective disorders including depression, migraine, headache and insomnia, comprises colloidal silver, gold and/or platinum and beta-aminoindole derivative
03/10/2011	DE102009039587A1 Neue Kombination New combination
03/10/2011	DE102009039546A1 Neue therapeutische Konzepte für die Behandlung von Fibromyalgien New therapeutic approaches for the treatment of fibromyalgia
03/10/2011	DE102009037514A1 Wasserlösliche Polysaccharidether und ihre Verwendung Water-soluble polysaccharide and their use
03/10/2011	CA2848827A1 Silicone modified fatty acids, method of preparation and usage thereof
03/10/2011	CA2809198A1 Combination medicament
03/10/2011	CA2806559A1 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
03/10/2011	CA2806539A1 Oral care methods and compositions utilizing chitosan-derivative compounds
03/10/2011	CA2805749A1 Pharmaceutical formulations and methods of use
03/10/2011	CA2777225A1 Granulated anthelmintic preparations and delivery systems
03/10/2011	CA2773146A1 P2x7: inhibition of epithelial cancers and papillomas
03/10/2011	CA2773131A1 Compositions and methods for treatment of leukemia
03/10/2011	CA2773038A1 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
03/10/2011	CA2773037A1 Clarithromycin extended-release tablet
03/10/2011	CA2773035A1 Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
03/10/2011	CA2773033A1 Use of aerosolized levofloxacin for treating cystic fibrosis
03/10/2011	CA2772992A1 Use of non-digestible oligosaccharides
03/10/2011	CA2772980A1 Neuroprotective ganglioside compositions for use in treating or diagnosing huntington's disease
03/10/2011	CA2772975A1 Novel multifunctional peptidase inhibitors, especially for medical use
03/10/2011	CA2772931A1 Compositions and methods for treatment of neuropathic pain
03/10/2011	CA2772916A1 Immunogenic compositions including tlr activity modulators
03/10/2011	CA2772878A1 Ganglioside transmucosal formulations
03/10/2011	CA2772877A1 Treatment of glaucoma and other retinopathies with gangliosides
03/10/2011	CA2772875A1 Methods of treating orthomyxoviral infections
03/10/2011	CA2772871A1 Pharmaceutical formulations for indibulin
03/10/2011	CA2772813A1 Iminosugars and methods of treating filoviral diseases
03/10/2011	CA2772807A1 Methods of treating poxviral infections
03/10/2011	CA2772790A1 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
03/10/2011	CA2772718A1 Compounds as tyrosine kinase modulators
03/10/2011	CA2772714A1 Heterocyclic compounds for the inhibition of pask
03/10/2011	CA2772642A1 Quinazolines as potassium ion channel inhibitors
03/10/2011	CA2772625A1 Compounds as tyrosine kinase modulators
03/10/2011	CA2772622A1 Ketorolac tromethamine compositions for treating or preventing ocular pain
03/10/2011	CA2772618A1 Fatty acid niacin conjugates and their uses
03/10/2011	CA2772616A1 Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
03/10/2011	CA2772614A1 Compounds and compositions for treating cancer
03/10/2011	CA2772484A1 Bis-benzimidazole derivatives
03/10/2011	CA2772354A1 Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
03/10/2011	CA2772328A1 Novel forms of a multicyclic compound
03/10/2011	CA2772265A1 Pyrazinylpyridines useful for the treatment of proliferative diseases
03/10/2011	CA2772218A1 Methods of treating mitochondrial disorders using metalloporphyrins
03/10/2011	CA2772212A1 Desferrithiocin polyether analogues and uses thereof
03/10/2011	CA2772194A1 Benzimidazole derivatives
03/10/2011	CA2772191A1 Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
03/10/2011	CA2772097A1 Methods for treating acute acoustic trauma
03/10/2011	CA2772080A1 Synthesis of a neurostimulative piperazine
03/10/2011	CA2772042A1 Antimicrobial medical dressings and protecting wounds and catheter sites
03/10/2011	CA2771822A1 Bruton's tyrosine kinase inhibitors
03/10/2011	CA2771747A1 Hot-melt extruded compositions containing plant-derived phenolic materials and processes for the preparation thereof
03/10/2011	CA2771592A1 Substituted heterocyclic derivatives for the treatment of pain and epilepsy
03/10/2011	CA2771568A1 Heteroaryl compounds as kinase inhibitors
03/10/2011	CA2771563A1 Bipyridines useful for the treatment of proliferative diseases
03/10/2011	CA2771472A1 Oxopiperazine derivatives for the treatment of pain and epilepsy
03/10/2011	CA2771352A1 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
03/10/2011	CA2771331A1 Substituted xanthine derivatives
03/10/2011	CA2771327A1 Chemical compounds
03/10/2011	CA2771123A1 Substituted xanthine derivatives
03/10/2011	CA2771097A1 Therapeutic aryl-amido-aryl compounds and their use
03/10/2011	CA2771061A1 Chromone derivatives, a process for their preparation and their therapeutic applications
03/10/2011	CA2771016A1 Kinase inhibitors, prodrug forms thereof and their use in therapy
03/10/2011	CA2770741A1 Novel antibacterial hydroxyphenyl compound
03/10/2011	CA2738117A1 Composition containing ultra-micronized palmitoyl-ethanolamide
03/10/2011	CA2694467A1 New method treatment the diseases, which use vitamin e oil in big doses so that of incurable (cancer, arthritis), chronic (diabetes, hypertension), infection (inflammation, virus,bacterium, fungus), regeneration damages (skin, tissue, conjunctive tissue), and in the look the applique, and covering by film
03/09/2011	EP2292771A2 Sense mRNA therapy
03/09/2011	EP2292632A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
03/09/2011	EP2292631A1 Regeneration of endogenous myocardial tissue by induction of neovascularization
03/09/2011	EP2292630A1 O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates
03/09/2011	EP2292629A1 Method of isolating cytisine from biomaterial
03/09/2011	EP2292625A1 Substituted spiro compounds and their use for producing pain-relief medicaments
03/09/2011	EP2292624A1 Process for the purification of olanzapine
03/09/2011	EP2292623A1 Acylated phthalocyanines
03/09/2011	EP2292622A1 New crystalline form of a triazolo(4,5-d)pyrimidine compound
03/09/2011	EP2292621A1 Vasopressin v1a antagonists
03/09/2011	EP2292620A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prohylaxis and treatment of disorders related thereto
03/09/2011	EP2292619A1 Purine derivatives for use as adenonsin A-2A receptor agonists
03/09/2011	EP2292617A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors
03/09/2011	EP2292616A1 Novel polymorphic form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
03/09/2011	EP2292615A1 Quinazoline compounds
03/09/2011	EP2292614A1 Substituted pyrimidines as aurora kinase inhibitors
03/09/2011	EP2292613A1 Dihydroindolinone derivatives
03/09/2011	EP2292612A2 Crystalline solvated forms of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
03/09/2011	EP2292611A1 Novel thiophenediamine derivative having urea structure
03/09/2011	EP2292610A1 Macrolides with VEGF transcription suppression activity
03/09/2011	EP2292609A1 Crystalline forms of rufinamide
03/09/2011	EP2292600A1 Crystaline forms VI and VII of atorvastatin calcium

1 ... 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 ... 7860